Dihydroartemisinin broke immune evasion through YAP1/JAK1/STAT1, 3 pathways to enhance anti-PD-1 therapy in hepatocellular carcinoma
Qing Peng(Peking University), Yi-Wei Liu(St. Jude Children's Research Hospital), Yu Xue(Dalian Medical University), Zhiqin Zhang(Hebei University of Chinese Medicine), Caige Li(Hebei University of Chinese Medicine), Yinglin Guo(Hebei University of Chinese Medicine), Liyuan Hao(Chengdu University of Traditional Chinese Medicine), Xinli Shi(Shanxi University), Yanmeng Zhao(Hebei University of Chinese Medicine), Shenghao Li(Hebei Medical University), Jingmin Ji(Hebei University of Chinese Medicine)
Cited by 0
Related Papers
Bclaf1 is an important NF-κB signaling transducer and C/EBPβ regulator in DNA damage-induced senescence
|Cell Death and Differentiation|2016|80
The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease
|Journal of Inflammation Research|2024|61
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
|Molecular Cancer|2022|57
The current status and future of PD-L1 in liver cancer
|Frontiers in Immunology|2023|55